🏢 官网IRSTOKCodex · 实盘不做把握 9/10
北京时间·🕒 发布 04:01:00时区推断·⟳ 抓取 04:02:45回填·⚡ 决策 07-17 04:03:57·102.7 天前
Stoke Therapeutics向新任CSO及新员工授予入职激励期权
这是纳斯达克规则下常规入职激励期权披露，核心内容是员工薪酬安排而非临床、监管、融资或商业化进展。
📄 原文STOK↗ 原文
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Skip to main navigation About Stoke Overview Leadership Founders Corporate Responsibility Scientific Platform Overview…
不做 Stoke Therapeutics（STOK.US）
例行员工入职激励期权披露，方向中性且事件对基本面和短线估值影响太小，不形成可执行交易。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-16 · 扩散 low · price-in 风险 low ↗
关键理由
- 这是纳斯达克规则下常规入职激励期权披露，核心内容是员工薪酬安排而非临床、监管、融资或商业化进展。
- 授予规模合计308070股期权，未改变zorevunersen管线、销售前景或公司现金流预期，难以形成短线同向交易催化。
主要风险
- 若后续另有Phase 3、监管或融资进展，应由新信号单独评估。
原文全文
展开原文 · 4,486 字
Skip to main navigation
About Stoke
Overview
Leadership
Founders
Corporate Responsibility
Scientific Platform
Overview
Tango
Publications
Disease Areas
Overview
Dravet Syndrome
ADOA
SYNGAP1
Pipeline
Patients & Families
Overview
Clinical Studies
Educational Resources
Careers & Culture
Overview
Job Opportunities
Diversity, Inclusion & Belonging
Investors & News
Overview
Media Room
Press Releases
Events & Presentations
Financials & SEC Filings
Stock Information
Analyst Coverage
Governance
Settlement Information
Contact Us
LinkedIn
Twitter
Menu
Press Release Details
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
July 16, 2026
PDF Version
BEDFORD, Mass. --(BUSINESS WIRE)--Jul. 16, 2026--
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on July 15, 2026 , it granted stock options to purchase shares of common stock to Thomas McCauley , the Company’s newly-appointed Chief Scientific Officer, and seven other new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4).
The company granted Mr. McCauley stock options to purchase 225,000 shares of common stock. The stock options that were granted have an exercise price of $29.91 per share, which is equal to the closing price of Stoke’s common stock on July 15, 2026 . Each option will vest over a 4-year period, with 1/4 th of the shares underlying the employee’s option vesting on the one-year anniversary of the applicable vesting commencement date and the remaining shares thereafter vesting monthly at a rate of 1/48 th of the shares underlying each employee’s option over the following 36 months, subject to the employee’s continued employment with Stoke on such vesting dates. The options have a term of 10 years and are subject to the terms and conditions of the 2023 Inducement Plan and the stock option agreement covering the grant.
In addition, the company granted stock options to purchase an aggregate of 83,070 shares of common stock to seven new employees. The stock options that were granted have an exercise price of $29.91 per share, which is equal to the closing price of Stoke’s common stock on July 15, 2026 . Each option will vest over a 4-year period, with 1/4 th of the shares underlying the employee’s option vesting on the one-year anniversary of the applicable vesting commencement date and the remaining shares thereafter vesting monthly at a rate of 1/48 th of the shares underlying each employee’s option over the following 36 months, subject to the employee’s continued employment with Stoke on such vesting dates. The options have a term of 10 years and are subject to the terms and conditions of the 2023 Inducement Plan and the stock option agreement covering the grant.
About Stoke Therapeutics
Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke’s first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study. Stoke’s initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for Stoke’s proprietary approach. Stoke is headquartered in Bedford, Massachusetts. For more information, visit https://www.stoketherapeutics.com/ and follow us on LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20260716006460/en/
Stoke Media & Investor Contacts:
Susan Willson
Vice President, Corporate Communications
swillson@stoketherapeutics.com
415-509-8202
Investor Relations
IR@stoketherapeutics.com
Source: Stoke Therapeutics, Inc.
Print Page
Email Alerts
Contact IR
Investor FAQs
About Stoke
Overview
Leadership
Founders
Corporate Responsibility
Scientific Platform
Overview
Tango
Publications
Disease Areas
Overview
Dravet Syndrome
ADOA
SYNGAP1
Pipeline
Patients & Families
Overview
Clinical Studies
Educational Resources
Careers & Culture
Overview
Job Opportunities
Diversity, Inclusion & Belonging
Investors & News
Overview
Media Room
Press Releases
Events & Presentations
Financials & SEC Filings
Stock Information
Analyst Coverage
Governance
Settlement Information
Contact Us
Menu
Press Release Details
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
July 16, 2026
PDF Version
BEDFORD, Mass. --(BUSINESS WIRE)--Jul. 16, 2026--
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on July 15, 2026 , it granted stock options to purchase shares of common stock to Thomas McCauley , the Company’s newly-appointed Chief Scientific Officer, and seven other new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4).
The company granted Mr. McCauley stock options to purchase 225,000 shares of common stock. The stock options that were granted have an exercise price of $29.91 per share, which is equal to the closing price of Stoke’s common stock on July 15, 2026 . Each option will vest over a 4-year period, with 1/4 th of the shares underlying the employee’s option vesting on the one-year anniversary of the applicable vesting commencement date and the remaining shares thereafter vesting monthly at a rate of 1/48 th of the shares underlying each employee’s option over the following 36 months, subject to the employee’s continued employment with Stoke on such vesting dates. The options have a term of 10 years and are subject to the terms and conditions of the 2023 Inducement Plan and the stock option agreement covering the grant.
In addition, the company granted stock options to purchase an aggregate of 83,070 shares of common stock to seven new employees. The stock options that were granted have an exercise price of $29.91 per share, which is equal to the closing price of Stoke’s common stock on July 15, 2026 . Each option will vest over a 4-year period, with 1/4 th of the shares underlying the employee’s option vesting on the one-year anniversary of the applicable vesting commencement date and the remaining shares thereafter vesting monthly at a rate of 1/48 th of the shares underlying each employee’s option over the following 36 months, subject to the employee’s continued employment with Stoke on such vesting dates. The options have a term of 10 years and are subject to the terms and conditions of the 2023 Inducement Plan and the stock option agreement covering the grant.
About Stoke Therapeutics
Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke’s first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study. Stoke’s initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for Stoke’s proprietary approach. Stoke is headquartered in Bedford, Massachusetts. For more information, visit https://www.stoketherapeutics.com/ and follow us on LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20260716006460/en/
Stoke Media & Investor Contacts:
Susan Willson
Vice President, Corporate Communications
swillson@stoketherapeutics.com
415-509-8202
Investor Relations
IR@stoketherapeutics.com
Source: Stoke Therapeutics, Inc.
Print Page
Email Alerts
Contact IR
Investor FAQs
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。